CY1111538T1 - Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου - Google Patents

Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου

Info

Publication number
CY1111538T1
CY1111538T1 CY20101100826T CY101100826T CY1111538T1 CY 1111538 T1 CY1111538 T1 CY 1111538T1 CY 20101100826 T CY20101100826 T CY 20101100826T CY 101100826 T CY101100826 T CY 101100826T CY 1111538 T1 CY1111538 T1 CY 1111538T1
Authority
CY
Cyprus
Prior art keywords
phosphoramid
compounds
nucleozitic
producers
cancer treatment
Prior art date
Application number
CY20101100826T
Other languages
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Cardiff Protides Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Protides Limited filed Critical Cardiff Protides Limited
Publication of CY1111538T1 publication Critical patent/CY1111538T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Φωσφοραμιδικά παράγωγα νουκλεοζιτικών ενώσεων όπως κλαδριβίνη, ισοκλαδριβίνη, φλουδαριβίνη και κλοφαραβίνη έχουν ενισχυμένη θεραπευτική δραστικότητα σε άνθρωπο, συγκεκριμένα, ενισχυμένη δραστικότητα αναφορικά με έναν καρκίνο όπως λευχαιμία. Καταλλήλως το φωσφοραμιδικό είναι υποκατεστημένο στο Ρ άτομο με Ar-O, όπου Ar είναι αρύλιο ή ετεροαρύλιο, εκάτερο εκ των οποίων μπορεί να είναι κατ' επιλογή υποκατεστημένο. Τύπος (I).
CY20101100826T 2005-03-21 2010-09-10 Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου CY1111538T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
EP06710096A EP1866324B1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1111538T1 true CY1111538T1 (el) 2015-08-05

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100826T CY1111538T1 (el) 2005-03-21 2010-09-10 Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου

Country Status (20)

Country Link
US (1) US8263575B2 (el)
EP (1) EP1866324B1 (el)
JP (2) JP5345381B2 (el)
CN (2) CN101175763A (el)
AT (1) ATE471334T1 (el)
AU (1) AU2006226182C1 (el)
BR (1) BRPI0609704B8 (el)
CA (1) CA2602324C (el)
CY (1) CY1111538T1 (el)
DE (1) DE602006014949D1 (el)
DK (1) DK1866324T3 (el)
ES (1) ES2348741T3 (el)
GB (1) GB0505781D0 (el)
IL (1) IL186104A (el)
MX (1) MX2007011666A (el)
PL (1) PL1866324T3 (el)
PT (1) PT1866324E (el)
SI (1) SI1866324T1 (el)
WO (1) WO2006100439A1 (el)
ZA (1) ZA200709011B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
HUE026235T2 (en) 2010-03-31 2016-06-28 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012092484A2 (en) * 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
DK2681227T3 (da) * 2011-03-01 2016-02-22 Nucana Biomed Ltd Phosphoramidatderivater af 5-fluor-2'-deoxyuridin til anvendelse i behandlingen af cancer
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
AU2016355429B2 (en) * 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) * 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
ES2256845T3 (es) 1995-04-21 2006-07-16 University Of South Florida Inmunopotencia de derivados de inosina monofosfato resistentes a 5'-nucleotidasa y utilizacion del mismo.
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
ATE212661T1 (de) * 1998-01-23 2002-02-15 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
US6949522B2 (en) * 2001-06-22 2005-09-27 Pharmasset, Inc. β-2′- or 3′-halonucleosides
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート

Also Published As

Publication number Publication date
WO2006100439A1 (en) 2006-09-28
PL1866324T3 (pl) 2010-12-31
US20090215715A1 (en) 2009-08-27
CN103936807A (zh) 2014-07-23
JP2013173786A (ja) 2013-09-05
ZA200709011B (en) 2009-01-28
ES2348741T3 (es) 2010-12-13
EP1866324B1 (en) 2010-06-16
GB0505781D0 (en) 2005-04-27
CA2602324C (en) 2015-02-24
IL186104A0 (en) 2008-01-20
IL186104A (en) 2013-06-27
ATE471334T1 (de) 2010-07-15
DE602006014949D1 (de) 2010-07-29
DK1866324T3 (da) 2010-09-27
BRPI0609704B8 (pt) 2021-09-28
AU2006226182B2 (en) 2011-09-01
US8263575B2 (en) 2012-09-11
JP5863702B2 (ja) 2016-02-17
SI1866324T1 (sl) 2010-10-29
BRPI0609704A2 (pt) 2010-04-20
EP1866324A1 (en) 2007-12-19
AU2006226182C1 (en) 2012-06-14
PT1866324E (pt) 2010-09-16
CN101175763A (zh) 2008-05-07
AU2006226182A1 (en) 2006-09-28
CA2602324A1 (en) 2006-09-28
MX2007011666A (es) 2007-11-14
JP2008533191A (ja) 2008-08-21
BRPI0609704B1 (pt) 2020-12-01
JP5345381B2 (ja) 2013-11-20

Similar Documents

Publication Publication Date Title
CY1111538T1 (el) Φωσφοραμιδικα παραγωγα νουκλεοζιτικων ενωσεων για χρηση στην αντιμετωπιση καρκινου
CY1120202T1 (el) Χημικες ενωσεις
CY1113647T1 (el) Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια
CY1124489T1 (el) Αναστολεις της hpk1 και μεθοδοι χρησης αυτων
CY1123919T1 (el) 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
CY1118526T1 (el) Παραγωγα διϋδροπυραζολοπυριμιδινονης
DE602007013252D1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
CY1117578T1 (el) Οπτοηλεκτρονικες διαταξεις με οργανομεταλλικους περοβσκιτες με μεικτα ανιοντα
CY1121244T1 (el) Συνδυασμος αναστολεα τελομερασης και γεμσιταβινής για τη θεραπεια του καρκινου
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1122835T1 (el) Συνδυαστικη θεραπεια
CY1113266T1 (el) Παραγωγο αρυλαμιδινης, αλας αυτου και αντιμυκητιασικο περιεχον αυτα
ATE443717T1 (de) Metastin derivate und ihre verwendung
CY1112570T1 (el) Θεραπεια καρκινων με μετασταση
CY1119402T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1109187T1 (el) Νεα μακρολιδια
SG11201901815WA (en) Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
PA8466101A1 (es) Agentes terapeuticos
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
ES2172474B1 (es) Derivados de glutarimida como agentes terapeuticos.
CY1111347T1 (el) Ενωσεις αμινοβενζοφαινονης υποκατεστημενες δια τριαζολης